COVID-19 testing provided by Empower subsidiary Kai Medical Laboratory
VANCOUVER BC / May 11, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) ("Empower" or the "Company") an integrated healthcare company - serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens - is pleased to announce pursuant to a Referral Agreement dated May 10, 2021 that a major Canadian airline will now refer its passengers to Kai Care for expedited COVID-19 testing.
As we work to close the chapter on these truly extraordinary times, people are looking to the near future to resume their pre-pandemic lives. While COVID-19 has fundamentally shifted the way we live, work and travel, reliable and efficient testing protocols are the key to living life fully in our new normal.
Today, Empower Clinics is announcing an agreement with a major Canadian airline, whereby passengers will have access to and benefit from a Kai Medical Laboratory COVID-19 test. Kai Care is a customized direct-to-consumer easy five step RT- PCR at Home Saliva Test Kit, that doesn't need to be administered by a health care provider.
When booking a flight or navigating the airline website passengers will have options to click a link to be referred to Kai Care websites www.kaitests.com and www.kaitests.ca to purchase an RT- PCR Kai Saliva Test Kit.
With most countries and airlines requiring pre-departure negative COVID-19 test results, travelers are encouraged to order enough test kits to use for pre-departure and for prior to their return. Kai Care provides test kits by UPS overnight courier in Canada, the United States and the Caribbean (excluding Mexico).
"Our industry leading COVID-19 tests are key to getting passengers back in their seats for business and leisure travel," said Steven McAuley, Chairman & CEO of Empower. "I am proud that a major Canadian airline has chosen Empower as a trusted supplier to assist with a safe restart for travel. Kai Care at home saliva tests offer passengers a convenient, non-invasive and private way to take a COVID-19 test during what can be a stressful travel preparation period."
Kai Medical Laboratory testing method is the gold standard, detecting the active SARS-CoV-2 (COVID-19) in patients that are symptomatic or asymptomatic. It also offers the option to test for a combination of COVID-19 and Influenza A/B, should the traveler wish. The test product and the method of test result reporting meet the current guidelines of executive travel orders to enable travelers the ability to complete the check-in, customs clearance and boarding requirements for flight travel.
This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics
ABOUT KAI MEDICAL LABORATORY:
Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company's COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and the travel industry.
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.
ON BEHALF OF THE BOARD OF DIRECTORS:
Chief Executive Officer
Steven McAuley CEO
Business Development & Communications
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley's franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market- leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that Kai Medical Laboratory will successfully win any US Government RFP; that the MedX Health pilot program will be successful; that Empower will place the MedX Health teledermatology product in health centers in North America; that the Company's products may not work as expected; that the Company may not be able to expand COVID-19 testing; that Air Canada will successfully refer travelers to Kai Care; that legislative changes may have an adverse effect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for Canadian clinics or Kai Medical Laboratory expansion in 2Q 2021; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
SOURCE: Empower Clinics Inc.
REPLY NEW MES
Spread the love. Be the first to like this post!
Recent EPWCF News
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 12/06/2022 06:20:21 PM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 11/03/2022 10:07:29 AM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 10/27/2022 08:48:52 PM
- Royal Caribbean Lays Keel for New Ship • TipRanks • 04/05/2022 06:26:06 PM
Hollywall Entertainment Inc., (OTC:HWAL) Announces the completion of its 2021 and 2020 Audit (s) • HWAL • Mar 24, 2023 12:48 PM
Glucose Health, Inc. Fiscal 2022 Annual Report • GLUC • Mar 23, 2023 3:23 PM
Nextech3D.ai Announces Its AI-Powered SaaS Platform Toggle3D Experiences A +963% Jump in Users in 60-Days Crossing Over 1000 Users • NTAR • Mar 23, 2023 7:07 AM
Lifecycle Assessment by Benchmark Shows TMC's NORI-D Nodule Project Could Outperform Land-Based Routes of Producing Nickel, Copper and Cobalt in Almost Every Impact Category Analyzed • TMC • Mar 22, 2023 1:44 PM
Fineqia Announces Partnership with Paris Blockchain Week to Accelerate Digital Asset Innovation • FNQQF • Mar 22, 2023 10:03 AM
E-Cite and ClearMarket Launch Nationwide EV Distribution Network Becoming the First All EV Dealership Opening in the Cerritos Auto Square, the World's Largest Automall • VAPR • Mar 22, 2023 9:41 AM